MT400 refers to Aralez’s proprietary combination of sumatriptan and naproxen sodium. MT400 has been approved by the U.S. Food and Drug Administration and is marketed under the trade name TREXIMET® (see below), by Pernix Therapeutics Holdings, Inc. (Pernix).
Aralez plans to file a New Drug Submission (NDS) for approval of MT400 in Canada in 2016.
To learn more, talk about MT400 with your pharmacist or other health care providers.
For Canadian practicing healthcare professionals and customers:
Customer Service By Phone: 1-800-639-0643
By Email: firstname.lastname@example.org
If you have a medical question regarding one of our products, please see the following:
By Phone: 1-866-391-4503
By Email: email@example.com